RegentAtlantic Capital’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $9.03M | Sell |
27,940
-3,958
| -12% | -$1.25M | 0.27% | 58 |
|
|
2022
Q2 | $10.3M | Buy |
31,898
+1,105
| +4% | +$332K | 0.34% | 53 |
|
|
2022
Q1 | $8.82M | Buy |
30,793
+375
| +1% | +$96.5K | 0.25% | 70 |
|
|
2021
Q4 | $8.4M | Buy |
30,418
+776
| +3% | +$197K | 0.23% | 78 |
|
|
2021
Q3 | $6.85M | Buy |
29,642
+5,124
| +21% | +$1.26M | 0.21% | 85 |
|
|
2021
Q2 | $5.63M | Buy |
24,518
+3,007
| +14% | +$604K | 0.17% | 103 |
|
|
2021
Q1 | $4.02M | Buy |
21,511
+9,543
| +80% | +$1.87M | 0.14% | 127 |
|
|
2020
Q4 | $2.02M | Buy |
11,968
+650
| +6% | +$97K | 0.08% | 168 |
|
|
2020
Q3 | $1.68M | Buy |
11,318
+472
| +4% | +$73.1K | 0.08% | 175 |
|
|
2020
Q2 | $1.78M | Buy |
10,846
+2,444
| +29% | +$375K | 0.1% | 165 |
|
|
2020
Q1 | $1.17M | Sell |
8,402
-504
| -6% | -$69.2K | 0.09% | 188 |
|
|
2019
Q4 | $1.17M | Hold |
8,906
| – | – | 0.07% | 217 |
|
|
2019
Q3 | $996K | Hold |
8,906
| – | – | 0.07% | 228 |
|
|
2019
Q2 | $987K | Buy |
8,906
+5,500
| +161% | +$648K | 0.07% | 228 |
|
|
2019
Q1 | $442K | Buy |
3,406
+256
| +8% | +$31.1K | 0.03% | 302 |
|
|
2018
Q4 | $365K | Buy |
3,150
+21
| +0.7% | +$2.35K | 0.03% | 312 |
|
|
2018
Q3 | $336K | Buy |
3,129
+320
| +11% | +$32K | 0.03% | 338 |
|
|
2018
Q2 | $240K | Sell |
2,809
-145
| -5% | -$11.9K | 0.02% | 374 |
|
|
2018
Q1 | $229K | Sell |
2,954
-310
| -9% | -$25K | 0.02% | 383 |
|
|
2017
Q4 | $276K | Buy |
3,264
+200
| +7% | +$17K | 0.02% | 365 |
|
|
2017
Q3 | $262K | Hold |
3,064
| – | – | 0.02% | 355 |
|
|
2017
Q2 | $252K | Hold |
3,064
| – | – | 0.02% | 362 |
|
|
2017
Q1 | $258K | Sell |
3,064
-40
| -1% | -$3.2K | 0.02% | 352 |
|
|
2016
Q4 | $228K | Sell |
3,104
-125
| -4% | -$9.31K | 0.02% | 359 |
|
|
2016
Q3 | $259K | Buy |
3,229
+21
| +0.7% | +$1.68K | 0.03% | 341 |
|
|
2016
Q2 | $253K | Sell |
3,208
-235
| -7% | -$17.7K | 0.02% | 343 |
|
|
2016
Q1 | $248K | Sell |
3,443
-545
| -14% | -$41.2K | 0.03% | 339 |
|
|
2015
Q4 | $336K | Sell |
3,988
-648
| -14% | -$53.8K | 0.04% | 298 |
|
|
2015
Q3 | $388K | Sell |
4,636
-175
| -4% | -$14.8K | 0.04% | 277 |
|
|
2015
Q2 | $402K | Sell |
4,811
-864
| -15% | -$65.8K | 0.04% | 277 |
|
|
2015
Q1 | $412K | Sell |
5,675
-578
| -9% | -$41.1K | 0.04% | 265 |
|
|
2014
Q4 | $431K | Sell |
6,253
-690
| -10% | -$46.6K | 0.04% | 272 |
|
|
2014
Q3 | $450K | Sell |
6,943
-412
| -6% | -$26.1K | 0.04% | 262 |
|
|
2014
Q2 | $457K | Buy |
7,355
+505
| +7% | +$30.1K | 0.04% | 259 |
|
|
2014
Q1 | $403K | Buy |
6,850
+440
| +7% | +$24.6K | 0.04% | 263 |
|
|
2013
Q4 | $327K | Buy |
6,410
+1,151
| +22% | +$57.6K | 0.03% | 290 |
|
|
2013
Q3 | $265K | Sell |
5,259
-1,094
| -17% | -$57.3K | 0.03% | 296 |
|
|
2013
Q2 | $312K | Buy |
+6,353
| New | +$346K | 0.04% | 270 |
|
Other funds holding LLY
RegentAtlantic Capital's LLY Position: Q3 2022 in Review
RegentAtlantic Capital reduced its Eli Lilly (LLY) stake by 12% in Q3 2022, selling an estimated $1.25M and leaving 27,940 shares worth $9.03M. The position accounts for 0.27% of the portfolio, ranked #58.
RegentAtlantic Capital first reported a position in LLY in Q2 2013 and has held it in 38 quarters since. The position peaked at $10.3M in Q2 2022. 2,484 funds tracked by Wall St. Rank hold LLY as of Q3 2022.
- RegentAtlantic Capital held 27,940 shares of Eli Lilly worth $9.03M as of Q3 2022.
- RegentAtlantic Capital sold 3,958 Eli Lilly shares in Q3 2022, an estimated $1.25M.
- Eli Lilly made up 0.27% of RegentAtlantic Capital's portfolio in Q3 2022, its #58 holding.
- RegentAtlantic Capital first reported a position in Eli Lilly in Q2 2013 and has held it in 38 quarters since.
- RegentAtlantic Capital's Eli Lilly position peaked at $10.3M in Q2 2022.
- 2,484 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2022.
Based on RegentAtlantic Capital's 13F filing for Q3 2022, filed 14 Nov 2022.